RxDoctor Payments Data

Stephany Ruszala, PA

Physician Assistant · North Tonawanda, NYNPI 1679253223

Payments from drug & device makers

$4,392in general payments, 2019–2025

Across 252 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$568
  • Boehringer Ingelheim$479
  • AstraZeneca$472
  • Amgen$421
  • Lilly USA, LLC$378
  • AbbVie$375
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,392100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,392 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$8,037
Medicare patients
46
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$34,742
TrulicityDulaglutide16$23,769
OzempicSemaglutide13$12,779
EliquisApixaban11$11,847
Diclofenac Epolamine11$7,942
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$7,149
MyrbetriqMirabegron13$6,904
SymbicortBudesonide/Formoterol Fumarate13$5,570
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,629
SynthroidLevothyroxine Sodium24$1,879
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen108$1,874
Levothyroxine Sodium102$1,612
Albuterol Sulfate HfaAlbuterol Sulfate50$1,583
Rosuvastatin Calcium96$1,568
Atorvastatin Calcium98$1,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$479$41,89136 claims
Lilly USA, LLCTrulicity$378$23,76916 claims
Novo NordiskOzempic$568$12,77913 claims
PfizerEliquis$44$11,84711 claims
Astellas Pharma US IncMyrbetriq$56$6,90413 claims
AstraZenecaSymbicort$472$5,57013 claims
AbbVieSynthroid$375$1,87924 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$123$1,612102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in North Tonawanda

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →